United Therapeutics has been granted a patent for an automated bioreactor system designed for organ decellularization. The system features a main chamber, perfusion pumps, pressure sensors, and a control system that automates the decellularization protocol based on real-time sensor inputs, including weight and pressure. GlobalData’s report on United Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on United Therapeutics, Cancer treatment biomarkers was a key innovation area identified from patents. United Therapeutics's grant share as of June 2024 was 42%. Grant share is based on the ratio of number of grants to total number of patents.
Automated system for organ decellularization protocol implementation
The granted patent US12022823B2 outlines a sophisticated system designed for the automatic implementation of a decellularization protocol for organs. Central to this system is a main chamber that houses the organ, equipped with a perfusion pressure sensor to monitor the liquid flow pressure, and a weight sensor to detect the organ's weight. The system also includes a perfusion pump that facilitates the liquid flow into the organ. A control system plays a pivotal role by receiving a predefined protocol detailing the steps necessary for the decellularization process. It utilizes inputs from the pressure and weight sensors to manage the perfusion pump, ensuring that the protocol is executed automatically. Notably, the control system can halt the current step based on weight input and transition to the next step, enhancing the precision of the decellularization process.
Additionally, the system allows for user interaction, enabling manual overrides of specific protocol steps and adjustments to the perfusion pump settings. This feature provides flexibility and adaptability during the decellularization process. Furthermore, the control system is designed to store and recall protocols upon user request, ensuring that established procedures can be easily accessed and reused. This combination of automated control and user input aims to improve the efficiency and effectiveness of organ decellularization, which is critical for various biomedical applications.
To know more about GlobalData’s detailed insights on United Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
